BioCentury | Nov 20, 2020
Translation in Brief

Long-term gene therapy study in dogs with hemophilia A; plus a comparison of HBV vaccine adjuvants and mAb that alleviates chemotherapy side effects

...factor relieves chemotherapy side effectsPublished in Cell Metabolism, Pfizer Inc. (NYSE:PFE) scientists found that the GDF15...
...platinum-based chemotherapy-induced anorexia and emesis in non-human primates. The side effects were also diminished in GDF15...
...cancer tumor-bearing mice receiving cisplatin. TARGETSGDF15 – Growth differentiation factor 15 Danielle Golovin University of Pennsylvania GlaxoSmithKline plc Sanofi Pfizer Inc. Factor VIII Growth differentiation factor 15 (GDF15) Infectious Hepatitis...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors...
...the immune-related function of GDF15 was first described in 2004. In a healthy human being, GDF15...
...have a miscarriage, leading to speculation that GDF15 protected the fetus from the maternal immune system.GDF15...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

...mAb that prevents cancer cachexia by blocking the interaction between GFRAL and RET, thus inhibiting GDF15-driven...
...ADAM10 - ADAM metallopeptidase domain 10 CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 GDF15...
...death 1 (PD-1) (PDCD1) (CD279) ADAM metallopeptidase domain 10 (ADAM10) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Growth differentiation factor 15 (GDF15) Ret...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...readout expected in 2020 is Phase I data for LA-GDF15, a long-acting formulation of human GDF15...
...and pig model, achieving plasma levels similar to a subcutaneous injection. Targets GCG - Glucagon GDF15...
BioCentury | Mar 26, 2019
Financial News

NGM could get $975M valuation in NASDAQ IPO

...Targets: FGF19 - Fibroblast growth factor 19; FGFR1c - Fibroblast growth factor receptor 1c isoform; GDF15...
BioCentury | Mar 22, 2019
Company News

Merck extends discovery partnership with NGM, drops obesity candidate

...exercisable in 2021. The pharma also said it is returning to NGM rights to its GDF15...
...body weight loss compared with placebo. Targets: FGFR1c - Fibroblast growth factor receptor 1c isoform; GDF15...
...factor 15; KLB - Klotho β Elizabeth S. Eaton, Staff Writer MK-3655 (NGM313) Merck & Co. Inc. NGM Biopharmaceuticals Inc. Growth differentiation factor 15 (GDF15)...
BioCentury | Oct 5, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

...Merck & Co. Inc. (NYSE:MRK) giving the pharma exclusive, worldwide rights to its program targeting growth differentiation factor 15 (GDF15)...
...those targeting FGF19. Next year, Merck plans to start two of NGM's engineered variants of GDF15...
...an antagonist of GDNF family receptor α like (GFRAL) designed to inhibit the effects of GDF15...
BioCentury | Oct 1, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

...Merck & Co. Inc. (NYSE:MRK) giving the pharma exclusive, worldwide rights to its program targeting growth differentiation factor 15 (GDF15)...
...those targeting FGF19. Next year, Merck plans to start two of NGM's engineered variants of GDF15...
...an antagonist of GDNF family receptor α like (GFRAL) designed to inhibit the effects of GDF15...
BioCentury | Jul 13, 2018
Company News

Novartis returns rights for Aveo's preclinical cachexia program

...NYSE:NVS; SIX:NOVN) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15)...
BioCentury | Jul 3, 2018
Company News

Novartis returns rights for Aveo's preclinical cachexia program

...SIX:NOVN; NYSE:NVS) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15)...
...for the AV-380 program. Aveo was up $0.04 to $2.32 on Tuesday. Jennie Walters AV-380 Aveo Pharmaceuticals Inc. Novartis AG Growth differentiation factor 15 (GDF15)...
Items per page:
1 - 10 of 25